Cor­bus brags about an­oth­er PhII suc­cess for its lead drug, but shares slide ear­ly

Cor­bus Phar­ma­ceu­ti­cals has plucked out some pos­i­tive da­ta from its mid-stage cys­tic fi­bro­sis study. But it didn’t help its stock price this morn­ing.

While the Phase II goal for its add-on drug an­aba­sum (JBT-101 or Re­sunab) was safe­ty and tol­er­a­bil­i­ty — which the biotech says they hit — it was an ef­fi­ca­cy sig­nal they picked up in a high-dose group that drew most of the at­ten­tion. There, the com­pa­ny says, a twice dai­ly 20 mg dose of the drug trig­gered a 75% re­duc­tion in the an­nu­al­ized rate of pul­monary ex­ac­er­ba­tions re­quir­ing IV an­tibi­otics com­pared to place­bo co­hort.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER